Related Experiment Videos
Dexamethasone for Parapneumonic Pleural Effusion: A Randomized, Double-Blind, Clinical Trial
Alfredo Tagarro1, Enrique Otheo2, Fernando Baquero-Artigao3
1Department of Pediatrics, University Hospital Infanta Sofía, San Sebastián de los Reyes, Spain; Biomedical School, Universidad Europea, Madrid, Spain.
The Journal of Pediatrics
|April 2, 2017
Summary
Dexamethasone (DXM) significantly shortened recovery time for children with parapneumonic pleural effusion. This steroid therapy proved safe and effective as an adjunctive treatment, reducing hospitalization duration.
Area of Science:
- Pediatric Pulmonology
- Clinical Pharmacology
- Infectious Diseases
Background:
- Parapneumonic pleural effusion is a common complication of community-acquired pneumonia in children.
- Current treatment guidelines lack specific recommendations for adjunctive therapies to expedite recovery.
- Identifying effective treatments to reduce the duration of illness and hospitalization is crucial.
Purpose of the Study:
- To evaluate the efficacy of dexamethasone (DXM) in reducing the time to recovery for pediatric patients diagnosed with parapneumonic pleural effusion.
- To assess the safety and tolerability of DXM when used as an adjunctive therapy.
Main Methods:
- A multicenter, randomized, double-blind, placebo-controlled trial involving 60 children (1 month to 14 years) with community-acquired pneumonia and pleural effusion.
- Participants received either intravenous DXM (0.25 mg/kg/dose every 6 hours for 48 hours) or a placebo, in addition to standard antibiotic treatment.
- The primary outcome was the objectively defined time to recovery; complications and adverse events were also monitored.
Main Results:
- Dexamethasone administration resulted in a significantly shorter time to recovery compared to placebo (median difference of 68 hours; P=0.037).
- The hazard ratio for recovery with DXM was 1.95 (95% CI, 1.10-3.45; P=0.021), indicating a faster recovery rate.
- No significant differences in complications were observed, apart from a higher incidence of hyperglycemia in the DXM group.
Conclusions:
- Dexamethasone demonstrates potential as a safe and effective adjunctive therapy for pediatric parapneumonic pleural effusion.
- The use of DXM may lead to a clinically meaningful reduction in the duration of illness and hospitalization.
- Further research could explore optimal dosing and patient selection for DXM therapy.